Serum antitrypsin activity and alpha1 antitrypsin level in atopic bronchial asthma.
The aim of our investigations was to evaluate the behavior of the important proteolitic inhibitor--serum alpha1 antitrypsin in patients with atopic and non-atopic bronchial asthma. The inhibitor concentration was determined by means of the immunodiffusion method, and antitrypsin activity was evaluated using the synthetic substrate BAPNA. The investigations were carried out on 53 patients with bronchial asthma and on 13 healthy persons. It was found that in some patients with atopic asthma alpha1 antitrypsin level and antitrypsin activity were very low but this did not lower significantly the mean value of the whole group. The results presented suggest that a relative alpha1 antitrypsin deficiency, at least in some patients, can be considered as being one of the pathogenetic factors in atopic asthma. In addition, determination of serum antitrypsin activity may be of practical significance in differential diagnosis of bronchial spastic reactions of bacterial and allergic origins.
D001249:Asthma / Q000201:enzymology* / Q000382:microbiology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000201:enzymology*; D014361:Trypsin Inhibitors / Q000378:metabolism*; D000515:alpha 1-Antitrypsin / Q000378:metabolism*
D014361:Trypsin Inhibitors; D000515:alpha 1-Antitrypsin